FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 4707 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis. PMID 39854662 · J Clin Oncol · 2025-May-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 2 Figure · 3 Panel · risk unclear |
| Primary percutaneous stenting above the ampulla versus endoscopic drainage for unresectable malignant hilar biliary obstruction (TESLA RCT): study protocol for a multicenter randomized controlled trial. PMID 40346549 · BMC Cancer · 2025-May-09 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort. PMID 40346047 · Nat Commun · 2025-May-09 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 2 Figure · 4 Panel · risk unclear |
| Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC. PMID 40349139 · Oncologist · 2025-May-08 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 1 Figure · 3 Panel · risk unclear |
| Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis. PMID 40340824 · BMC Cancer · 2025-May-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML. PMID 39775763 · Blood · 2025-May-08 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma. PMID 39652675 · N Engl J Med · 2025-May-08 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial. PMID 40328753 · Signal Transduct Target Ther · 2025-May-07 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 1 Figure · 2 Panel · risk unclear |
| Comparison of Electronic Surveillance With Routine Monitoring for Patients With Lymphoma at High Risk of Relapse: Prospective Randomized Controlled Phase 3 Trial (Sentinel Lymphoma). PMID 40327037 · JMIR Cancer · 2025-May-06 The trial is a Phase III randomized oncology study with a time-to-event primary endpoint (detection of relapse/progression), but the intervention is a digital surveillance tool, not a drug. Therefore, it does not meet the drug intervention criterion for inclusion in the KM digitization cohort. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Laparoscopic versus open distal gastrectomy with d2 lymphadenectomy in treatment of locally T4A gastric cancer: the protocol of a randomized controlled trial. PMID 40316937 · BMC Surg · 2025-May-02 干预为非药物单独策略,未满足药物干预要求。 |
H
S
B
|
严格 v3 独有 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. PMID 40198940 · Eur J Cancer · 2025-May-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306. PMID 40179821 · Eur J Cancer · 2025-May-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial. PMID 40139004 · Eur J Cancer · 2025-May-02 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial. PMID 40139003 · Eur J Cancer · 2025-May-02 The report is a quality-of-life analysis of a Phase III randomized trial in oncology. While it meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result, it does not have a primary or key secondary time-to-event efficacy endpoint as required. The endpoint is quality of life, which is excluded per adjudication rules. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Radiation vs. trans-oral surgery for treatment de-escalation in HPV-related oropharyngeal cancers: Primary analysis of the ORATOR2 randomized trial. PMID 40121836 · Eur J Cancer · 2025-May-02 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Adjuvant chemotherapy compared to observation in resected biliary tract cancers: Survival meta-analysis of phase-III randomized controlled trials. PMID 40101432 · Eur J Cancer · 2025-May-02 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial. PMID 40332939 · JAMA Netw Open · 2025-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Immunotherapy Strategies After Immune Checkpoint Inhibitor Exposure in Renal Cell Carcinoma: A Review. PMID 40146173 · JAMA Oncol · 2025-May-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial. PMID 40019493 · Clin Cancer Res · 2025-May-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | no_km 0 Figure · 0 Panel · risk not_applicable |
| Justification, margin values, and analysis populations for oncologic noninferiority and equivalence trials: a meta-epidemiological study. PMID 39657246 · J Natl Cancer Inst · 2025-May-01 The record is a meta-epidemiological study analyzing the design and reporting of Phase III randomized oncology trials, not an original result report of a specific drug-containing trial. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial. PMID 39656951 · J Natl Cancer Inst · 2025-May-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer. PMID 39656603 · Clin Cancer Res · 2025-May-01 The study is a secondary analysis of biomarker association within a Phase III randomized trial (NRG/RTOG 9512) of radiation fractionation. It meets criteria for oncology, human, randomized, phase 3, and time-to-event endpoints, but the intervention is radiation alone, not a drug-containing regimen. Therefore, it is excluded. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prognostic impact of RDI of vincristine in patients with DLBCL receiving R-CHOP: a supplementary analysis of JCOG0601. PMID 40453132 · Blood Neoplasia · 2025-May 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 3 Figure · 5 Panel · risk visible |
| Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial. PMID 40441802 · ESMO Open · 2025-May The record is from the DESTINY-Breast06 Phase III randomized trial, which is oncology, human, randomized, and drug-intervening. However, this specific abstract and record focus exclusively on patient-reported outcome (PRO) endpoints and quality of life (QOL) deterioration, which are secondary or health-related outcomes, not the primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS) required for the cohort. The primary efficacy results (time-to-event) are mentioned as background but are not reported here. Therefore, it is excluded based on report type. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study. PMID 40407887 · Ann Hematol · 2025-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | no_km 0 Figure · 0 Panel · risk not_applicable |
| Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study). PMID 40403198 · JCO Glob Oncol · 2025-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Health-related quality of life in patients with aggressive non-Hodgkin lymphoma: results from the PETAL trial. PMID 40397196 · Ann Hematol · 2025-May The record is a quality-of-life analysis from a Phase III randomized trial with a drug intervention. While it meets criteria for oncology, human, randomized, phase, drug intervention, and original result, it is excluded because the report's primary focus and presented endpoint is not a time-to-event efficacy endpoint. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of gastrectomy on efficacy and safety of second-line chemotherapy patients with advanced gastric cancer: Exploratory analysis of two randomized phase III trials. PMID 40385345 · Ann Gastroenterol Surg · 2025-May 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 2 Figure · 4 Panel · risk visible |
| Assessment of whether use of a professional medical writer is associated with time to publication of papers reporting phase III oncology clinical trials in two high-impact general medicine journals. PMID 40372172 · Curr Med Res Opin · 2025-May 未发现恶性肿瘤人群证据。 |
H
S
B
|
严格 v3 独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Assessing Algorithmic Fairness With a Multimodal Artificial Intelligence Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III Trials. PMID 40344545 · JCO Clin Cancer Inform · 2025-May The record describes a secondary analysis of a multimodal AI algorithm using data from five Phase III trials. While the underlying trials were Phase III randomized, the report itself is not a primary result report of a drug intervention trial; it evaluates an AI tool's performance, not a drug's efficacy. The drug intervention criterion is not established for this specific report. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON. PMID 40334315 · ESMO Open · 2025-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | no_km 0 Figure · 0 Panel · risk not_applicable |
| Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study. PMID 40331625 · Future Oncol · 2025-May The record is a Phase III, randomized, oncology trial with a drug intervention and is an original result report. However, it does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) or associated Kaplan-Meier/HR analysis. It is a safety/secondary analysis focusing on patient-reported adverse events. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials. PMID 40306832 · Lancet Haematol · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial. PMID 40306831 · Lancet Haematol · 2025-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Relationship Between Best Tumor Shrinkage and Progression-Free Survival and Overall Survival in Patients With Progressive Midgut Neuroendocrine Tumors Treated With [177Lu]Lu-DOTA-TATE: Ad Hoc Analysis of the Phase III NETTER-1 Trial. PMID 40272146 · Cancer Med · 2025-May This is an ad hoc analysis from the primary NETTER-1 trial, investigating a secondary question (correlation of tumor shrinkage with survival). It is not the original primary result report of the randomized trial, which would compare [177Lu]Lu-DOTA-TATE vs. control for efficacy. The intervention is constant within the arm being analyzed, so this report does not represent the trial's primary drug-intervention comparison. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Induction versus Concurrent Chemotherapy for Advanced Nasopharyngeal Carcinoma. PMID 40261119 · NEJM Evid · 2025-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial. PMID 40250457 · Lancet Oncol · 2025-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| The Impact of Uncommon HRR Alterations as Predictors of Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials. PMID 40246801 · Target Oncol · 2025-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1-mutated, metastatic breast cancer. PMID 40222048 · Future Oncol · 2025-May 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 1 Figure · 1 Panel · risk unclear |
| Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial. PMID 40220771 · Lancet Oncol · 2025-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Operationalizing intermediate clinical endpoints: A pragmatic framework for prostate cancer management trials. PMID 40215591 · Cancer Treat Rev · 2025-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine). PMID 40209292 · ESMO Open · 2025-May 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | no_km 0 Figure · 0 Panel · risk not_applicable |
| Safety and efficacy outcomes of delta‑like ligand 3 inhibitors for the treatment of solid tumors: A systematic review and single‑arm meta‑analysis. PMID 40110579 · Oncol Lett · 2025-May 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | no_km 0 Figure · 0 Panel · risk not_applicable |
| Mepitel® film versus standard care for the prevention of skin toxicity in breast cancer patients treated with adjuvant radiotherapy: A randomized controlled trial. PMID 40110362 · Clin Transl Radiat Oncol · 2025-May 干预为非药物单独策略,未满足药物干预要求。 |
H
S
B
|
严格 v3 独有 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Evaluation of surrogate endpoints in phase III randomized control trials of advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. PMID 40080137 · Eur J Clin Pharmacol · 2025-May 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306. PMID 40075024 · Adv Ther · 2025-May 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 1 Figure · 2 Panel · risk visible |
| Nomogram predicting the outcome of salvage radiation therapy for prostate-specific antigen failure following radical prostatectomy: an exploratory analysis of a randomized, multicenter, open-label, phase 3 trial (JCOG0401). PMID 40056276 · Int J Clin Oncol · 2025-May The record describes an exploratory analysis of a Phase III randomized trial for prostate cancer with a time-to-event endpoint. However, it does not meet the core eligibility criterion of having a drug-containing intervention; the intervention is salvage radiation therapy. Therefore, it is excluded. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial. PMID 40055521 · Nat Med · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. PMID 40044930 · Nat Med · 2025-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 2 Figure · 4 Panel · risk unclear |
| Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial). PMID 40044552 · Dig Liver Dis · 2025-May 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |